TORVANTA
Other · S&P 500 · data as of 2026-10-05

ALKS stock analysis: ALKS

ALKS (ALKS) is an S&P 500 company in Other. It grades weakest on growth and value.

The model's view of ALKS · subscribers

Where ALKS ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with ALKS · updated 2026-10-05 · from prices and SEC filings

ALKS price performance

ALKS against the S&P 500, one year
+0%+50%ALKS +47%S&P 500 +18%2025-09-292026-10-05
Year to date+52.8%S&P 500 +14.5% · ahead by 38.3 pts
1 year+37.7%S&P 500 +17.0% · ahead by 20.6 pts
3 years+50.3%S&P 500 +89.3% · behind by 38.9 pts
5 years+38.5%S&P 500 +91.3% · behind by 52.8 pts

Total returns with dividends reinvested.

ALKS factor grades

Each grade compares ALKS with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

D-ValueP/E 112.5x (industry 20.1x)FCF yield 3.1% (industry 6.0%)
DGrowthRevenue growth +11% (industry +8%)EPS growth -82% (industry +10%)
CProfitabilityOperating margin 7.0% (industry 9.6%)ROIC 2.8% (industry 10.1%)
CMomentum12-month change +38%From 52-wk high -23%

ALKS in plain numbers

ALKS key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$7.2B
Revenue growth (y/y)+11%
Free-cash-flow yield3.1%
Dividend yieldn/a
Next earnings (expected)2026-10-27
Valuation measures
Market value$7.2B
Enterprise value$8.2B
P/E (trailing)112.5x
Forward P/E (Torvanta estimate)153.9x
Price / sales4.3x
Price / book4.0x
EV / revenue4.9x
EV / EBITDA45.6x
Financial highlights
Revenue, last 12 months$1.7B
Net income, last 12 months$66.1M
EPS, last 12 months (GAAP)$0.38
Gross margin84.6%
Operating margin7.0%
Net margin4.0%
Return on equity3.9%
Return on invested capital2.8%
Cash$511.5M
Total debt$1.5B
Debt / equity0.83x
Free cash flow, last 12 months$221.6M
Interest cover2.0x
Current ratio2.30x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

ALKS earnings trends

Revenue vs earnings
-$66.5M$74.1M$214.8M$355.4M$496.0MSep 2024 Revenue: $378.1MDec 2024 Revenue: $430.0MMar 2025 Revenue: $306.5MJun 2025 Revenue: $390.7MSep 2025 Revenue: $394.2MDec 2025 Revenue: $384.5MMar 2026 Revenue: $392.9MJun 2026 Revenue: $496.0MSep 2024 Net income: $92.4MDec 2024 Net income: $146.5MMar 2025 Net income: $22.5MJun 2025 Net income: $87.1MSep 2025 Net income: $82.8MDec 2025 Net income: $49.3MMar 2026 Net income: -$66.5MJun 2026 Net income: $501KSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: 24.4%Net margin: 34.1%Net margin: 7.3%Net margin: 22.3%Net margin: 21.0%Net margin: 12.8%Net margin: -16.9%Net margin: 0.1%-17%9%34%■ Revenue ■ Net income ━ Net margin
Earnings per share$-0.4$-0.1$0.2$0.6$0.9Sep 2024 EPS (GAAP, diluted): $0.6Dec 2024 EPS (GAAP, diluted): $0.9Mar 2025 EPS (GAAP, diluted): $0.1Jun 2025 EPS (GAAP, diluted): $0.5Sep 2025 EPS (GAAP, diluted): $0.5Dec 2025 EPS (GAAP, diluted): $0.3Mar 2026 EPS (GAAP, diluted): $-0.4Jun 2026 EPS (GAAP, diluted): $0.0Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Sep 2025 -11% · Dec 2025 -67% · Mar 2026 -408% · Jun 2026 -100%

From the company's 10-Q and 10-K filings with the SEC.

ALKS financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$1.2B$1.1B$1.7B$1.6B$1.5B
Net income-$48.2M-$158.3M$355.8M$367.1M$241.7M
EPS (GAAP)$-0.30$-0.97$2.09$2.16$1.43
Free cash flow$73.7M-$17.2M$353.3M$405.6M$480.3M

ALKS earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-07-28$0.00-100%+27%-7.0%
2026-05-05$-0.40-408%+28%+1.2%
2026-02-25$0.29-67%-11%-8.2%
2026-01-12$0.29-67%-11%-1.7%
2025-10-28$0.49-11%+4%+5.5%
2025-10-22$0.49-11%+4%-4.5%

About ALKS

HeadquartersDublin 4, Ireland
Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Listed onNasdaq
FormerlyANTLER SCIENCE TWO PLC, Antler Science Two Ltd

From the company's SEC registration record.

Companies similar to ALKS

CompanyMarket valueP/ERevenue growthOperating margin12-month change
ALKS ALKS$7.2B112.5x+11%7.0%+38%
ALGM ALGM$7.2Bn/a+24%4.9%+36%compare
ACA ACA$7.2B14.7x+3%11.8%+59%compare
POWL POWL$7.2B38.0x+7%19.7%+96%compare
VSXY VSXY$7.1B19.9x+10%7.9%+207%
FSS FSS$7.1B25.1x+24%16.2%-1%
APPF APPF$7.2B46.6x+21%17.5%-18%

All Other stock ratings

Frequently asked questions

Is ALKS stock a buy?

Torvanta does not tell individuals what to buy. Its grades for ALKS are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

What is ALKS's P/E ratio?

ALKS trades at about 112.5 times its last 12 months of GAAP earnings reported to the SEC, and about 153.9 times Torvanta's own estimate of the next 12 months.

When does ALKS report earnings next?

Based on its filing history, Torvanta expects ALKS to report around 2026-10-27.

How has ALKS performed against the S&P 500?

Over the past year ALKS returned +37.7%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer